Eli Lilly (NYSE:LLY) Surges 5% Following Breakthrough BRAVE-AA-PEDS Study Results
Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...
Health.com8d
Zepbound Is Now Available in Additional Doses at Lower Costs
Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Eli Lilly has reduced the prices of certain ...
Fierce Pharma10d
AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longer
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
NBC 10 Philadelphia8d
Amgen starts two critical late-stage trials for weight loss drug MariTide
The peptides activate receptors of a gut hormone called GLP-1, while the antibody blocks receptors of another hormone called GIP. That's unlike Eli Lilly's obesity drug, Zepbound, which activates ...